Ace BioSciences, an emerging pharma company developing novel protein-based vaccines and antibodies to address infectious diseases, and CLC bio announce a collaborative bioinformatics agreement
Ingelise Saunders, chief executive officer at Ace BioSciences said: "At Ace BioSciences we place considerable emphasis on selecting partners based on their scientific know-how - and in that regard we recognise CLC bio as the leading company within bioinformatics, with a global reputation and internationally renowned experts.
"We see this collaboration as a significant opportunity to augment and expand our bioinformatics platform to increase efficiency, enhance our analyses, and accelerate our research".
Jannick Bendtsen, project manager and senior scientific officer at CLC bio commented: "We are looking forward to this collaboration, which is scientifically interesting and challenging.
"The implementation of our customised software will streamline and fast-track analysis and further increase statistical confidence in the selection of novel candidates for inclusion in the Ace BioSciences development portfolio.
"Implementation of automated target validation protocols will increase efficiency and the rate of data throughput, improve quality assurance and enhance data security".
CLC bio will upgrade and expand Ace BioSciences's existing bioinformatics platform to ensure the company is taking advantage of the most up-to-date, relevant, and innovative software, including state-of-the-art protein vaccine target characterisation.
In addition, CLC bio will provide greater integration and cross-referencing capabilities, securing for Ace BioSciences the ability to apply more extensive statistical analyses to its databases and laboratory information.
CLC bio's customised approach will strengthen Ace BioSciences's ability to compare, rank, and prioritise potential vaccine targets.
It consists of a number of CLC workbenches for DNA, RNA, and protein sequence analysis, supplemented with customised bioinformatics modules that are proprietary for Ace BioSciences.
